Europeiska unionen - spanska - EMA (European Medicines Agency)

mylan ireland limited - fingolimod clorhidrato de - la esclerosis múltiple remitente-recurrente - inmunosupresores - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 y 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Europeiska unionen - spanska - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - ondansetron hidrocloruro dihidrato - soluciÓn inyectable - 8 mg inyectable 4 ml - ondansetron hidrocloruro dihidrato 2 mg - ondansetrón

Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - ciclosporina para microemulsion - cÁpsula blanda - 25 mg - ciclosporina para microemulsion 25 mg - ciclosporina

Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - capecitabina - comprimido recubierto con pelÍcula - 150 mg - capecitabina 150 mg - capecitabina

Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - capecitabina - comprimido recubierto con pelÍcula - 500 mg - capecitabina 500 mg - capecitabina

Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - azitromicina dihidrato - polvo para suspensiÓn oral - 500 mg - azitromicina dihidrato 500 mg - azitromicina

Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - amlodipino - comprimido - 10 mg - amlodipino 10 mg - amlodipino

Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - amlodipino - comprimido - 5 mg - amlodipino 5 mg - amlodipino

Spanien - spanska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - amisulprida - comprimido recubierto con pelÍcula - 400 mg - amisulprida 400 mg - amisulprida